Switching from usual brand cigarettes to a tobacco-heating cigarette or snus: Part 2. Biomarkers of exposure

Biomarkers

Volumn 20, Issue 6-7, 2015, Pages 391-403

  Ogden, Michael W ^a   Marano, Kristin M ^a   Jones, Bobbette A ^b   Morgan, Walter T ^b   Stiles, Mitchell F ^b  

^a RAI Services Company   (United States)

^b R J REYNOLDS TOBACCO COMPANY   (United States)

Author keywords

Mouth level exposure; multi center randomized study; risk continuum; tobacco and tobacco smoke constituents; yield in use

Indexed keywords

1,3 BUTADIENE; ACROLEIN; ACRYLAMIDE; AROMATIC AMINE; BENZENE; BIOLOGICAL MARKER; CARBOXYHEMOGLOBIN; CHAR LINE; COTININE; CROTONALDEHYDE; NICOTINE; POLYCYCLIC AROMATIC HYDROCARBON; TAR; UNCLASSIFIED DRUG; AMINE; AROMATIC HYDROCARBON; NICOTINE GUM;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; EXPOSURE; HUMAN; MULTICENTER STUDY; MUTAGENICITY; RANDOMIZED CONTROLLED TRIAL; SMOKING; TOBACCO; TOBACCO EXPOSURE; TOBACCO HEATING CIGARETTE; URINALYSIS; BLOOD; CLINICAL TRIAL; FEMALE; MALE; MIDDLE AGED; PREVENTION AND CONTROL; PROCEDURES; SMOKELESS TOBACCO; SMOKING CESSATION; TIME FACTOR; URINE; UTILIZATION;

ADULT; AMINES; BIOMARKERS; FEMALE; HUMANS; HYDROCARBONS, AROMATIC; MALE; MIDDLE AGED; NICOTINE; SMOKING; TIME FACTORS; TOBACCO USE CESSATION; TOBACCO USE CESSATION PRODUCTS; TOBACCO, SMOKELESS;

EID: 84948720048     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2015.1094134     Document Type: Article

References (52)

1. Adhikari B, Kahende J, Malarcher A, et al. (2008). Smoking-attributable mortality, years of potential life lost, and productivity losses-United States, 2000-2004. MMWR 57: 1226-8
2. Agency for Toxic Substances and Disease Registry (ATSDR). (2007). Toxicological profile for acrolein. Available from: http://www.atsdr.cdc.gov/toxprofiles/tp124.pdf [last accessed 2 Aug 2014]
3. Benowitz NL, Dains KM, Hall SM, et al. (2009). Progressive commercial cigarette yield reduction: biochemical exposure and behavioral assessment. Cancer Epidemiol Biomarkers Prev 18: 876-83
4. Bodnar JA, Morgan WT, Murphy PA, Ogden MW. (2012). Mainstream smoke chemistry analysis of samples from The 2009 US cigarette market. Regul Toxicol Pharmacol 64: 35-42
5. Borgerding MF, Bodnar JA, Curtin GM, Swauger JE. (2012). The chemical composition of smokeless tobacco: a survey of products sold in The United States in 2006 and 2007. Regul Toxicol Pharmacol 64: 367-87
6. Borgerding M, Klus H. (2005). Analysis of complex mixtures-cigarette smoke. Exp Toxicol Pathol 57: 43-73
7. Byrd GD, Davis RA, Ogden MW. (2005). A rapid LC-MS-MS method for The determination of nicotine and cotinine in serum and saliva samples from smokers: validation and comparison with a radioimmunoassay method. J Chromatogr Sci 43: 133-40
8. Byrd GD, Ogden MW. (2003). Liquid chromatographic/tandem mass spectrometric method for The determination of The tobacco-specific nitrosamine metabolite NNAL in smokers' urine. J Mass Spectrom 38: 98-107
9. Carmella SG, Chen M, Han S, et al. (2009). Effects of smoking cessation on eight urinary tobacco carcinogen and toxicant biomarkers. Chem Res Toxicol 22: 734-41
10. Hatsukami DK, Benowitz NL, Rennard SI, et al. (2006). Biomarkers to assess The utility of potential reduced exposure tobacco products. Nicotine Tob Res 8: 600-22
11. Hecht SS. (2002). Human urinary carcinogen metabolites: biomarkers for investigating tobacco and cancer. Carcinogenesis 23: 907-22
12. Hecht SS, Carmella SG, Le KA, et al. (2004). Effects of reduced cigarette smoking on levels of 1-hydroxypyrene in urine. Cancer Epidemiol Biomarkers Prev 13: 834-42
13. International Agency for Research on Cancer (IARC). (2004). Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum 83: 1-1452
14. International Conference on Harmonization (ICH). 1996. Guidance for industry E6 good clinical practice: consolidated guidance. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073122.pdf [last accessed 2 Aug 2014]
15. Joseph AM, Hecht SS, Murphy SE, et al. (2005). Relationships between cigarette consumption and biomarkers of tobacco toxin exposure. Cancer Epidemiol Biomarkers Prev 14: 2963-8
16. Kado NY, Langley D, Eisenstadt E. (1983). A simple modification of The Salmonella liquid-incubation assay. Increased sensitivity for detecting mutagens in human urine. Mutat Res 121: 25-32
17. Kotlyar M, Hertsgaard LA, Lindgren BR, et al. (2011). Effect of oral snus and medicinal nicotine in smokers on toxicant exposure and withdrawal symptoms: a feasibility study. Cancer Epidemiol Biomarkers Prev 20: 91-100
18. Lee PN. (2013). The effect of reducing The number of cigarettes smoked on risk of lung cancer, COPD, cardiovascular disease and FEV(1)-a review. Regul Toxicol Pharmacol 67: 372-81
19. Lee EM, Malson JL, Moolchan ET, Pickworth WB. (2004). Quantitative comparisons between a nicotine delivery device (Eclipse) and conventional cigarette smoking. Nicotine Tob Res 6: 95-102
20. Lewalter J, Gries W. (2000). Hemoglobin adducts for aromatic amines: aniline, o-, m-, p-toluidine, o-anisidine, p-chloroaniline, alpha- and beta-naphthylamine, 4-aminodiphenyl, benzidine, 4,4′-diaminodiphenylmethane, 3,3′-dichlorobenzidine. In: Angerer J, Schaller KH., eds. Analyses of hazardous substances in biological materials. Vol. 7. Weinheim: Wiley-VCH, 191-218
21. Leroy CM, Jarus-Dziedzic K, Ancerewica D, et al. (2012). Reduced exposure evaluation of an electrically heated cigarette system. Part 7: a one-month, randomized, ambulatory, controlled clinical study in Poland. Reg Tox Pharm 64: S74-84
22. Marano KM, Naufal ZS, Borgerding MB, Potts RJ. (2012). Quantitative risk assessment of tobacco-burning and tobacco-heating cigarettes. Rec Adv Tobacco Sci 38: 3-20
23. Mascher DG, Mascher HJ, Scherer G, Schmid ER. (2001). High-performance liquid chromatographic-tandem mass spectrometric determination of 3-hydroxypropylmercapturic acid in human urine. J Chromatogr B Biomed Sci Appl 750: 163-9
24. Meger M, Meger-Kossien I, Schuler-Metz A, et al. (2002). Simultaneous determination of nicotine and eight nicotine metabolites in urine of smokers using liquid chromatography-tandem mass spectrometry. J Chromatogr B 778: 251-61
25. Mendes P, Kapur S, Wang J, et al. (2008). A randomized, controlled exposure study in adult smokers of full flavor Marlboro cigarettes switching to Marlboro Lights or Marlboro Ultra Lights cigarettes. Regul Toxicol Pharmacol 51: 295-305
26. Nelson PR, Chen P, Dixon M, Steichen T. (2011). A survey of mouth level exposure to cigarette smoke in The United States. Regul Toxicol Pharmacol 61: S25-38
27. Nutt DJ, Phillips LD, Balfour D, et al. (2014). Estimating The harms of nicotine-containing products using The MCDA approach. Eur Addict Res 20: 218-25
28. Ogden MW, Marano KM, Jones BA, et al. (2015a). Switching from usual brand cigarettes to a tobacco-heating cigarette or snus: Part 3. Biomarkers of biological effect. Biomarkers. [Epub ahead of print]. doi: 10.3109/1354750X.2015.1094135
29. Ogden MW, Marano KM, Jones BA, Stiles MF. (2015b). Switching from usual brand cigarettes to a tobacco-heating cigarette or snus: Part 1. Study design and methodology. Biomarkers. [Epub ahead of print]. doi: 10.3109/1354750X.2015.1094133
30. Richter E, Rösler S, Scherer G, et al. (2001). Haemoglobin adducts from aromatic amines in children in relation to area of residence and exposure to environmental tobacco smoke. Int Arch Occup Environ Health 74: 421-8
31. Riedel K, Scherer G, Engl J, et al. (2006). Determination of three carcinogenic aromatic amines in urine of smokers and nonsmokers. J Anal Toxicol 30: 187-95
32. Roethig HJ, Feng S, Liang Q, et al. (2008). A 12-month, randomized, controlled study to evaluate exposure and cardiovascular risk factors in adult smokers switching from conventional cigarettes to a second-generation electrically heated cigarette smoking system. J Clin Pharmacol 48: 580-91
33. Sarkar M, Liu J, Koval T, et al. (2010). Evaluation of biomarkers of exposure in adult cigarette smokers using Marlboro snus. Nicotine Tob Res 12: 105-16
34. Scherer G, Frank S, Riedel K, et al. (2000a). Biomonitoring of exposure to polycyclic aromatic hydrocarbons of nonoccupationally exposed persons. Cancer Epidemiol Biomarkers Prev 9: 373-80
35. Scherer G, Meger M, Meger-Kossien I, Pachinger A. (2000b). Biological monitoring of The tobacco-smoke related exposure to acrolein. Proc Am Assoc Cancer Res 42: 150
36. Scherer G, Meger M, Meger-Kossien I, Pachinger A. (2001). Biological monitoring of The tobacco-smoke related exposure to benzene. Proc Am Assoc Cancer Res 41: 146
37. Scherer G, Urban M, Hagedorn HW, et al. (2010). Determination of methyl-, 2-hydroxyethyl- and 2-cyanoethylmercapturic acids as biomarkers of exposure to alkylating agents in cigarette smoke. J Chromatogr B Analyt Technol Biomed Life Sci 878: 2520-8
38. Sexton K. (2006). Biomarkers of toxicant exposure. In: DeCaprio AP., ed. Toxicologic biomarkers. New York: Taylor & Francis, 39-62
39. Seyler TH, Bernert JT. (2011). Analysis of 4-aminobiphenyl in smoker's and nonsmoker's urine by tandem mass spectrometry. Biomarkers 16: 212-21
40. Smith CJ, McKarns SC, Davis RA, et al. (1996). Human urine mutagenicity study comparing cigarettes which burn or primarily heat tobacco. Mutat Res 361: 1-9
41. Stratton K, Shetty P, Wallace R, Bondurant S. (2001). Clearing The smoke: The science base for tobacco harm reduction-executive summary. Tob Control 10: 189-95
42. Talaska G, Al-Zoughool M. (2003). Aromatic amines and biomarkers of human exposure. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 21: 133-64
43. Uchida K, Kanematsu M, Sakai K, et al. (1998). Protein-bound acrolein: potential markers for oxidative stress. Proc Natl Acad Sci USA 95: 4882-7
44. US Department of Health and Human Services (USDHHS). (1989). Reducing The health consequences of smoking: 25 years of progress: a report of The surgeon general. Atlanta (GA): US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health
45. US Department of Health and Human Services (USDHHS). (2004). The health consequences of smoking: a report of The surgeon general. Atlanta (GA): US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health
46. Urban M, Gilch G, Schepers G, et al. (2003). Determination of The major mercapturic acids of 1,3-butadiene in human and rat urine using liquid chromatography with tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 796: 131-40
47. Urban M, Kavvadias D, Riedel K, et al. (2006). Urinary mercapturic acids and a hemoglobin adduct for The dosimetry of acrylamide exposure in smokers and nonsmokers. Inhal Toxicol 18: 831-9
48. US Congress. (2009). Family Smoking Prevention and Tobacco Control Act, Public Law 111-31, 123 Stat. 1776. Available from: http://www.gpo.gov/fdsys/pkg/PLAW-111publ31/html/PLAW-111publ31.htm [last accessed 2 Aug 2014]
49. van Sittert NJ, Megens HJ, Watson WP, Boogaard PJ. (2000). Biomarkers of exposure to 1,3-butadiene as a basis for cancer risk assessment. Toxicol Sci 56: 189-202
50. Wagner BM., Eclipse Expert Panel. (2000). A safer cigarette? A comparative study. A consensus report. Inhal Tox 12: 1-48
51. Yang M, Koga M, Katoh T, Kawamoto T. (1999). A study for The proper application of urinary naphthols, new biomarkers for airborne polycyclic aromatic hydrocarbons. Arch Environ Contam Toxicol 36: 99-108
52. Zeller M, Hatsukami D., Strategic Dialogue on Tobacco Harm Reduction Group. (2009). The strategic dialogue on tobacco harm reduction: a vision and blueprint for action in The US. Tob Control 18: 324-32